| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Jaguar Health, Inc.: Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society Congress in Support of Company's Expanding Focus on Cancer Supportive Care | 363 | ACCESSWIRE | Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called "chemo mouth") in Q3 2024Company to feature "Make Cancer Less Shitty" patient advocacy... ► Artikel lesen | |
| 18.04. | Jaguar Health, Inc.: Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care | 454 | ACCESSWIRE | Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and... ► Artikel lesen | |
| 17.04. | Jaguar Health, Inc. - 10-K/A, Annual Report | 39 | SEC Filings | ||
| 16.04. | Why Is Jaguar Health (JAGX) Stock Up 44% Today? | 71 | InvestorPlace | ||
| 16.04. | Why Jaguar Health Stock Is Up Today | 29 | Benzinga.com | ||
| 16.04. | Jaguar Health, Inc.: Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care | 560 | ACCESSWIRE | Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription productOral mucositis, also called "chemo mouth," has emerged as the most significant adverse event... ► Artikel lesen | |
| 10.04. | Jaguar Health shareholders approve reverse stock split | 85 | Seeking Alpha | ||
| 10.04. | What Is Going on With Jaguar Health (JAGX) Stock Today? | 39 | InvestorPlace | ||
| 09.04. | Jaguar Health, Inc. - 8-K, Current Report | 27 | SEC Filings | ||
| 09.04. | Why Jaguar Health Stock Is Soaring After-Hours | 42 | Benzinga.com | ||
| 09.04. | Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders | 413 | ACCESSWIRE | Company not implementing a reverse split at this timeTop line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrheaSAN... ► Artikel lesen | |
| 08.04. | Jaguar Health, Inc.: Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement | 260 | ACCESSWIRE | Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrheaSAN FRANCISCO, CA / ACCESSWIRE / April 8, 2024 / Jaguar Health... ► Artikel lesen | |
| 02.04. | Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript | 22 | Insider Monkey | ||
| 02.04. | Jaguar Health, Inc.: Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International | 182 | ACCESSWIRE | Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S.Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for... ► Artikel lesen | |
| 02.04. | Earnings call: Jaguar Health focuses on cancer support amid revenue dip | 24 | Investing.com | ||
| 01.04. | Jaguar Health, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 6 | SEC Filings | ||
| 01.04. | Jaguar Health, Inc.: Jaguar Health Reports 2023 Financial Results | 454 | ACCESSWIRE | Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18%Net Q4 2023 revenue of approximately... ► Artikel lesen | |
| 01.04. | Jaguar Health, Inc. - 10-K, Annual Report | 16 | SEC Filings | ||
| 27.03. | Jaguar Health, Inc.: Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates | 413 | ACCESSWIRE | Click here to register for April 1 investor webcastCompany plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023SAN FRANCISCO, CA / ACCESSWIRE / March... ► Artikel lesen | |
| 21.03. | Jaguar Health, Inc. - 8-K, Current Report | 64 | SEC Filings |
Seite:
1 2 3 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 623 |
| NVIDIA | 414 |
| DEUTSCHE BANK | 402 |
| BAYER | 317 |
| NEL | 296 |
| TESLA | 275 |
| TUI | 238 |
| RHEINMETALL | 232 |
| BYD | 231 |
| SUPER MICRO COMPUTER | 217 |
| BASF | 181 |
| THYSSENKRUPP | 177 |
| COMMERZBANK | 161 |
| AMAZON | 159 |
| MICROSOFT | 154 |
| PLUG POWER | 153 |
| RWE | 150 |
| AIXTRON SE | 149 |
| META PLATFORMS | 135 |
| INTEL | 134 |
| ALPHABET | 132 |
| GALERIA KARSTADT KAUFHOF GMBH | 130 |
| DELIVERY HERO | 128 |
| MERCEDES-BENZ | 127 |
| PAYPAL | 124 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
